Mizuho Initiates Coverage On Maze Therapeutics with Outperform Rating, Announces Price Target of $97
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. MAZE | 0.00 |
Mizuho analyst Salim Syed initiates coverage on Maze Therapeutics (NASDAQ:
MAZE) with a Outperform rating and announces Price Target of $97.
